JNJ

226.97

+0.64%↑

ABT

93.9

+1.65%↑

MDT

81.82

-1.36%↓

115.47

-0.09%↓

VEEV

160.15

-0.9%↓

JNJ

226.97

+0.64%↑

ABT

93.9

+1.65%↑

MDT

81.82

-1.36%↓

115.47

-0.09%↓

VEEV

160.15

-0.9%↓

JNJ

226.97

+0.64%↑

ABT

93.9

+1.65%↑

MDT

81.82

-1.36%↓

115.47

-0.09%↓

VEEV

160.15

-0.9%↓

JNJ

226.97

+0.64%↑

ABT

93.9

+1.65%↑

MDT

81.82

-1.36%↓

115.47

-0.09%↓

VEEV

160.15

-0.9%↓

JNJ

226.97

+0.64%↑

ABT

93.9

+1.65%↑

MDT

81.82

-1.36%↓

115.47

-0.09%↓

VEEV

160.15

-0.9%↓

Home・Elenco Azioni・Savara Inc

Savara Inc

Aperta

SettoreSettore sanitario

5.06 -3.8

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

5.03

Massimo

5.29

Metriche Chiave
By Trading Economics
Entrata	-2.7M -32M
Dipendenti	70
EBITDA	-3.9M -33M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+114.84% upside

Dividendi
By Dow Jones
Utili prossimi	11 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	43M 1.1B
Apertura precedente	8.86
Chiusura precedente	5.06

Notizie sul Sentiment di mercato

By Acuity

100%

343 / 348 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Neutral Evidence

2.76 / 2.84 Supporto e resistenza

Savara Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

27 apr 2026, 23:15 UTC

Principali Notizie su Eventi

U.K. Consumers Pay Less But Full Impact of Mideast War to Be Seen

27 apr 2026, 23:08 UTC

Utili

I principali Market Mover

LendingClub Shares Gain on 1Q Profit, Revenue Beat

27 apr 2026, 23:58 UTC

Utili

Samsung SDI 1Q Net Profit Beat FactSet-Compiled Consensus

27 apr 2026, 23:58 UTC

Utili

Samsung SDI 1Q Net KRW56.10B Vs. Loss KRW216.00B >006400.SE

27 apr 2026, 23:56 UTC

Utili

Samsung SDI 1Q Oper Loss KRW155.60B Vs. Loss KRW434.10B >006400.SE

27 apr 2026, 23:56 UTC

Utili

Samsung SDI 1Q Rev KRW3.576T Vs. KRW3.177T >006400.SE

27 apr 2026, 23:48 UTC

Discorsi di Mercato

Nikkei May Remain Rangebound Amid Uncertainty Over Iran Conflict -- Market Talk

27 apr 2026, 23:42 UTC

Discorsi di Mercato

Australian Consumer Confidence Making a Slow Come Back -- Market Talk

27 apr 2026, 23:34 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Gold Edges Higher as Investors Assess Iran's Proposal to U.S. -- Market Talk

27 apr 2026, 23:30 UTC

Discorsi di Mercato

Australia's NDIS Could Lose 'Social Licence' If Not Reined In -- Market Talk

27 apr 2026, 23:08 UTC

Discorsi di Mercato

Polymetals's Revenue Outlook 'Extraordinary' for a Small-Cap Stock -- Market Talk

27 apr 2026, 23:02 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

27 apr 2026, 23:02 UTC

Discorsi di Mercato

Warsh Will Probably Lean a Bit More Dovish Than Powell -- Market Talk

27 apr 2026, 22:42 UTC

Discorsi di Mercato

BOJ Expected to Keep Rates On Hold; Guidance to Skew Hawkish -- Market Talk

27 apr 2026, 22:10 UTC

Utili

Haier Smart Home: Results Also Weighed by Weak Demand in China-U.S. Markets >600690.SH

27 apr 2026, 22:09 UTC

Utili

Haier Smart Home: Increase in Tariff Costs, Extreme Weather Conditions Hurt Results >600690.SH

27 apr 2026, 22:09 UTC

Utili

Haier Smart Home 1Q Net CNY4.65B Vs. Net CNY5.49B >600690.SH

27 apr 2026, 22:09 UTC

Utili

Haier Smart Home 1Q Rev CNY73.69B Vs. CNY79.12B >600690.SH

27 apr 2026, 21:56 UTC

Utili

Tsingtao Brewery: Cost Controls Among Factors Supporting Results >0168.HK

27 apr 2026, 21:55 UTC

Utili

Tsingtao Brewery 1Q Net CNY1.80B Vs. Net CNY1.71B >0168.HK

27 apr 2026, 21:55 UTC

Utili

Tsingtao Brewery 1Q Rev CNY10.29B Vs. CNY10.45B >0168.HK

27 apr 2026, 21:44 UTC

Utili

Tianqi Lithium: Higher Demand for Products From EV Sector Also Boosted Financial Performance >002466.SZ

27 apr 2026, 21:43 UTC

Utili

Tianqi Lithium: Increase in Average Selling Prices of Major Lithium Products Supported Results >002466.SZ

27 apr 2026, 21:41 UTC

Utili

Tianqi Lithium 1Q Rev CNY5.13B Vs. CNY2.58B >002466.SZ

27 apr 2026, 21:41 UTC

Utili

Tianqi Lithium 1Q Net CNY1.88B Vs. Net CNY104.27M >002466.SZ

27 apr 2026, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

27 apr 2026, 20:50 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Basic Materials Roundup: Market Talk

27 apr 2026, 20:50 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Financial Services Roundup: Market Talk

27 apr 2026, 20:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

27 apr 2026, 20:39 UTC

Utili

Nucor: Operating Segments Earnings Growth Driven by Trade Policies That Continue to Reduce Flood of Unfairly Traded Imports Into U.S. >NUE

Confronto tra pari

Modifica del prezzo

Savara Inc Previsione

Obiettivo di Prezzo

By TipRanks

114.84% in crescita

Previsioni per 12 mesi

Media 11 USD 114.84%

Alto 16 USD

Basso 9 USD

Basato su 6 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Savara Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

6 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 6 che hanno fornito valutazioni azionarie a Savara Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

2.76 / 2.84Supporto e resistenza

The bullish and bearish events are balanced.

All events are bullish.

Bullish events outweigh bearish events.

Sentiment

By Acuity

343 / 348 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Savara Inc

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.